<DOC>
	<DOCNO>NCT00350766</DOCNO>
	<brief_summary>The purpose study determine cell therapy efficacy patient ST elevation acute myocardial infarction ( STEMI )</brief_summary>
	<brief_title>Cell Therapy Myocardial Infarction</brief_title>
	<detailed_description>This study protocol describe randomize double blind clinical trial , main purpose evaluate effect autologous bone marrow mononuclear cell ( ABMMC ) implant 300 Brazilian patient ST elevation acute myocardial infarction ( STEMI ) . Double blind study design choose trial , base several phase I II safety trial intracoronary autologous bone marrow stem cell transplantation , already publish . The study coordinator committee , support Brazilian Health Ministry , therefore propose phase III trial purpose prove efficacy kind therapy , population high risk develop heart failure death cardiovascular cause . Thus , protocol propose prospective , double blind , control randomize trial evaluate effect ABMMC transplantation intracoronary infusion , systolic leave ventricle ( LV ) function . The main hypothesis trial patient submit autologous bone marrow stem cell implant , 6 month follow , present 5 % relative increase ejection fraction ( EF ) compare control group .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Patients eligible present characteristic describe : ST segment elevation myocardial infarction two contiguous lead , accord WHO definition , least one follow two : ) Presence chest pain . ii ) Elevation myonecrosis marker . Age 30 80 year old . Ejection fraction â‰¤50 % Echocardiogram ( Simpson ) segmentary dysfunction infarction area , measure 3rd 5th day post AMI . Among patient submit thrombolytic therapy , angioplasty related artery preferably do 24h thrombolysis , maximum deadline 72h thrombolysis . Patients ineligible present characteristic describe : AMI relate artery present TIMI &lt; 3 moment f cell injection . Left Main Coronary Artery Lesion &gt; 50 % multivessel coronariopathy ( &gt; 70 % lesion vessel &gt; 2,0mm diameter leave anterior descending , circumflex right coronary territory ) indicate need CABG angioplasty three stent implant . Coronary anatomy , thrombolytic reperfusion , present need angioplasty stent implant . Final Diastolic Pression LV high 30 mmHg ventriculography evaluate EF inclusion criterion research protocol ( item `` c '' inclusion criterion ) . Cardiac arrest Killip IV AMI admission need ventilatory support . Cardiogenic shock persist third day AMI ( need Intraaortic balloon pump vasopressor ) . AMI mechanical complication ( ventricular septal defect , papillary muscle rupture , leave ventricular free wall rupture ) . Significant valve disease , define aortic stenosis ( mean systolic pressure gradient across aortic valve &gt; 50mmHg ) , mitral stenosis valvar area le 1,5 cm,2 moderate severe aortic and/or mitral regurgitation . Chronic use immunosuppressive agent . &gt; 2,0 mg/dl creatinine previous dialysis treatment . Presence fever past 48h injection glare active systemic infection accord ACCP/SCCM ( American College Chest Physicians/Society Critical Care Medicine ) sepsis definition . Sustained ventricular tachycardia 48h AMI . Illicit drug abuse alcohol abuse ( base DSM IV ) . Any co morbidity , survival impact two year . Myocarditis Active liver disease COPD continuous steroid use . Hematological disease , neoplasm , bone disease hemostatic disturbance . Inflammatory disease chronicle infectious disease . Presence definitive implantation cardiac pace maker cardiac defibrillator . Impossibility reach cell suspension 100 million mononuclear cell due cell paucity bone marrow aspirate .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Ventricular Remodeling</keyword>
	<keyword>Bone Marrow Cell Transplantation</keyword>
	<keyword>Stem cell</keyword>
</DOC>